NKTR · Nektar Therapeutics · Webcasts, Transcripts & Audio
$36.29
-0.98 (-2.63%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.28B
Shares
34.21M
Volume · Nov 16
214.15K
Avg daily vol (3M)
1.1M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Nektar Therapeutics Webcasts
Earnings calls, investor updates, investor days and conferences for Nektar Therapeutics (NKTR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Nektar Therapeutics (NKTR) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Nektar Therapeutics (NKTR) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-12
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
Confident tone
RESPEG Phase III registrational progress
Alopecia areata development
Vitiligo expansion
Revenue
$9.39M
▼ 20.4% YoY Diluted EPS
$-1.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-10-01
Nektar Therapeutics (NKTR) October 1, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-13
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Confident tone
Market research and first-line positioning for ResPeg
Atopic dermatitis dosing durability
Alopecia areata Phase 3 / long-term extension
Revenue
$10.13M
▼ 9.3% YoY Diluted EPS
$-1.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Nektar Therapeutics (NKTR) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Confident tone
Atopic dermatitis (ectopic dermatitis) program
Alopecia areata program
Regulatory risk on moderate-population expansion
Revenue
$10.86M
▲ 3.8% YoY Diluted EPS
$-1.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-04-20
Nektar Therapeutics (NKTR) April 20, 2026 Investor Update Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-12
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Confident tone
Rezpeg/Respag in atopic dermatitis
Rezpeg in alopecia areata
Phase 3 readiness and regulatory alignment
Revenue
$21.81M*
▼ 25.3% YoY Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Confident tone
Alopecia areata Phase IIb (RESOLVE-AA)
REZPEG in atopic dermatitis (RESOLVE-AD)
Phase III planning and FDA interactions
Revenue
$11.79M
▼ 51.1% YoY Diluted EPS
$-1.87
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Confident tone
REZPEG/rezpegaldesleukin lead program
Atopic dermatitis Phase IIb REZOLVE-AD results
FDA Fast Track and Phase III planning
Revenue
$11.18M
▼ 52.4% YoY Diluted EPS
$-2.95
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Positive tone
REZPEG in atopic dermatitis (REZOLVE-AD)
Early-stage pipeline (TNFR2 agonist)
REZPEG in alopecia areata
Revenue
$10.46M
▼ 51.7% YoY Diluted EPS
$-3.62
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call
Revenue
$29.18M*
▲ 22.1% YoY Gross margin
72.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
Confident tone
REZPEG in atopic dermatitis
REZPEG in alopecia areata
NKTR-255 oncology program
Revenue
$24.12M
▼ 0.1% YoY Diluted EPS
$-2.66
Gross margin
81.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call
Revenue
$23.49M
▲ 14.6% YoY Diluted EPS
$-3.76
Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Nektar Therapeutics (NKTR) Q1 2024 Earnings Call Transcript
Confident tone
REZPEG in atopic dermatitis
REZPEG in alopecia areata
NKTR-0165 TNFR2 agonist
Revenue
$21.64M
▲ 0.2% YoY Diluted EPS
$-2.85
Gross margin
60.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-04
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
Confident tone
REZPEG in atopic dermatitis
REZPEG in alopecia areata
TNFR2 / NKTR-0165 program
Revenue
$23.89M*
▲ 8.5% YoY Gross margin
69.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
Revenue
$24.14M
▲ 2.2% YoY Diluted EPS
$-3.60
Gross margin
48.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
Revenue
$20.50M
▼ 5% YoY Diluted EPS
$-4.05
Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-17
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Revenue
$21.59M
▼ 13% YoY Diluted EPS
$-10.95
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Nektar Therapeutics (NKTR) Q4 2022 Earnings Call
Revenue
$22.02M*
▼ 11.9% YoY Gross margin
71.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Nektar Therapeutics (NKTR) Q3 2022 Earnings Call Transcript
Revenue
$23.62M
▼ 5.2% YoY Diluted EPS
$-4.65
Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Nektar Therapeutics (NKTR) Q2 2022 Earnings Call Transcript
Revenue
$21.59M
▼ 23.8% YoY Diluted EPS
$-12.75
Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Nektar Therapeutics (NKTR) Q1 2022 Earnings Call
Revenue
$24.82M
▲ 5% YoY Diluted EPS
$-7.35
Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Nektar Therapeutics (NKTR) Q4 2021 Earnings Call Transcript
Revenue
$25.01M
▲ 6.6% YoY Diluted EPS
$-11850.00
Gross margin
75.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript
Revenue
$24.92M
▼ 17% YoY Diluted EPS
$-10.50
Gross margin
78.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript
Revenue
$28.33M
▼ 42% YoY Diluted EPS
$-10.35
Gross margin
72.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript
Revenue
$23.65M
▼ 53.2% YoY Diluted EPS
$-10.20
Gross margin
75.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript
Revenue
$23.46M
▼ 30.7% YoY Diluted EPS
$-9.75
Gross margin
81.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Nektar Therapeutics (NKTR) Q3 2020 Earnings Call Transcript
Revenue
$30.03M
▲ 2.8% YoY Diluted EPS
$-9.15
Gross margin
81.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Nektar Therapeutics (NKTR) Q2 2020 Earnings Call Transcript
Revenue
$48.85M
▲ 109.5% YoY Diluted EPS
$-6.75
Gross margin
88.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
Revenue
$50.57M
▲ 79.2% YoY Diluted EPS
$-11.70
Gross margin
92.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Nektar Therapeutics (NKTR) Q4 2019 Earnings Call
Revenue
$33.86M
▼ 15% YoY Diluted EPS
$-9.60
Gross margin
82.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
906709
CUSIP
640268306
13F (30d)
199 filings
164 filers
Visit website
Investor relations